

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 17, 2025

PE anti-mouse H-2Kb

RRID:AB_313735

Type: Antibody

Proper Citation

(BioLegend Cat# 116508, RRID:AB_313735)

Antibody Information

URL: http://antibodyregistry.org/AB_313735

Proper Citation: (BioLegend Cat# 116508, RRID:AB_313735)

Target Antigen: H-2Kb

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse H-2Kb

Description: This monoclonal targets H-2Kb

Target Organism: mouse

Clone ID: Clone AF6-88.5

Antibody ID: AB_313735

Vendor: BioLegend

Catalog Number: 116508

Alternative Catalog Numbers: 116507

Record Creation Time: 20231110T045001+0000

Record Last Update: 20241115T074540+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse H-2Kb.

No alerts have been found for PE anti-mouse H-2Kb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Ingelshed K, et al. (2024) MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors. *iScience*, 27(6), 109862.

Delaunay T, et al. (2024) Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity. *Cell reports. Medicine*, 5(5), 101528.

Linde IL, et al. (2023) Neutrophil-activating therapy for the treatment of cancer. *Cancer cell*, 41(2), 356.

Tello-Lafoz M, et al. (2021) Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. *Immunity*, 54(5), 1037.

Lu SX, et al. (2021) Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. *Cell*, 184(15), 4032.